Skip to content
PeerVoice Brain & Behaviour Video cover art

All Episodes

PeerVoice Brain & Behaviour Video — 80 episodes

#
Title
1

Silvia Messina, MD, DPhil / Michael Levy, MD, PhD - Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) or Something Else? How to Tell the Difference

2

Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?

3

Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum

4

Ashkan Shoamanesh, MD, FRCPC - Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?

5

Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

6

Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact

7

Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition

8

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

9

Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis

10

Bernhard Suter, MD - Rett Syndrome Uncovered: An International Exchange on Recognition, Monitoring, and Emerging Therapies

11

Richard B. Lipton, MD - Overcoming the Disconnects Between Recommendations and Reality in Acute Migraine Treatment: Patient and Provider Perspectives on Communication and Collaboration

12

Vijay Ramaswamy, MD, PhD, FRCPC / Sébastien Perreault, MD, FRCPC / Lucie Lafay-Cousin, MD - Spot, Act, and Treat: Canadian Consensus Updates on Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

13

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

14

Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice

15

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

16

Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies

17

Luis Querol, MD, PhD - 2025 Congress Highlights From Edinburgh, Scotland: Breaking Down the Data Driving Novel Therapeutic Developments in CIDP

18

Ashkan Shoamanesh, MD, FRCPC - Can We Find a New Way Forward in Secondary Stroke Prevention? Exploring the Rationale and Potential Roles for Factor XIa Inhibition

19

Vijay Ramaswamy, MD, PhD, FRCPC - Spotting Rare Disease in Practice: Neurofibromatosis Type 1 With Plexiform Neurofibromas

20

Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG

21

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

22

Gavin Giovannoni, MBBCh, PhD - Navigating and Pioneering High-Efficacy DMT Strategies: Optimizing Patient Outcomes in Multiple Sclerosis

23

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

24

Andrew Frank, MD, BScH, FRCPC - Decoding the Evidence Around Anti-Amyloid Therapies for Alzheimer’s Disease: Expert Insights for Clinical Practice

25

Elena Pischik, MD, PhD - Acute Polyneuropathy With Abdominal Pain: Could It be Acute Hepatic Porphyria?

26

Serdar Dalkilic, MD - Menstruation Triggering Severe Unexplained Abdominal Pain: Could It Be Acute Hepatic Porphyria?

27

Olivier Bonnot, MD, PhD - Acute Psychosis: When to Suspect Acute Hepatic Porphyria

28

Darren M. Brenner / Benoît Coffin - If I'd Known Then What I Know Now: Recognising My First AHP Patient

29

Darren M. Brenner, MD - If I'd Known Then What I Know Now: Recognising My First AHP Patient (Rebroadcast)

30

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

31

Andrew Frank, MD, BScH, FRCPC - Beyond Amyloid: Neuroinflammation as a Key Treatment Target in Alzheimer’s Disease

32

Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data

33

Zaeem Siddiqi, MD, PhD - Tailoring Treatment for Hereditary Transthyretin Amyloidosis Polyneuropathy: The Evolution of Care

34

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

35

Angela Fitch, MD, FACP, MFOMA - This Cannot Weight: A Specialist Guide to Weight Management and Obesity Associated With Emotional Eating Behaviours

36

Bruce A C Cree, MD, PhD, MAS - BTK Inhibition and Beyond: Novel Therapies in MS

37

Mandar Jog, MD - Addressing Unmet Needs in the Management of Cervical Dystonia: Updates to Care

38

Geneviève Matte, MDCM, FRCPC - Improving Early Diagnosis of hATTR Amyloidosis: A Critical Step Towards Better Outcomes

39

Deborah Siegal, MD, MSc, FRCPC / Richard Body, MBChB, FRCEM, PhD - Turn the Bleed Around: Expert Perspectives on the Evolving Evidence for Management of Factor Xa Inhibitor-Associated Life-Threatening Bleeding

40

Jiwon Oh, MD, PhD, FRCPC - Navigating the High-Efficacy DMT Landscape in MS: Integrating New Data and Real-World Evidence

41

Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML

42

Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making

43

Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis

44

Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy

45

Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia

46

Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?

47

Ali Aamer Habib, MD - Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies for Generalised Myasthenia Gravis

48

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

49

Carel le Roux, MD, PhD - Prioritising Obesity Care in Our Clinical Practices: Why We Must and How We Can

50

Laurent Servais, MD, PhD - Catch Them Before They Fall: A Call to Action for Comprehensive Testing for Hypotonia in Paediatric Patients

51

Andreea Ciudin, MD, PhD - Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on the Modernisation of Obesity Care

52

Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers

53

Martin Katzman, BSc, MD, FRCPC - Unveiling the Truth: A Look at the Hidden Burden of Alopecia Areata and the Urgency to Improve Assessment

54

Jacqueline Turner, MSc - Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing

55

Nicholas Johnson, MD, MSci, FAAN - Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnosis Is Needed

56

P. James B. Dyck, MD - When ATTR Amyloidosis Strikes a Nerve: Best Practices in Timely Suspicion, Diagnosis, and Management of ATTR-Polyneuropathy

57

Michael Thorpy, MD - Dual Duty: Protecting Cardiovascular Health in Patients With Narcolepsy

58

James F. Howard Jr, MD - Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors

59

Vijay Ramaswamy, MD, PhD, FRCPC - Managing the Pediatric Patient With Plexiform Neurofibromas: The Case for Systemic Therapy

60

Sharon Cohen, MD, FRCPC - Inflammation and the Brain: Why We Need To Know More

61

K. Jennifer Ingram, MD, FRCPC Moderator - Untangling the Web of Alzheimer’s Disease: Why Early Diagnosis Today May Shape a Better Tomorrow for Patients

62

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

63

Graeme C Black, OBE, DPhil, FRCOphth, FMedSci - Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing

64

Janaka Karalliedde, FRCP, PhD - Stroke Prevention in T2DM: The Neuroprotective Benefits of GLP-1 RAs

65

Melanie J. Davies, CBE, FRCP, FMedSci - Proactive Stroke Risk Mitigation Strategies: Taking Aim in Type 2 Diabetes

66

Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics

67

Managing Generalised Myasthenia Gravis: A Tale of Two Targets

68

Lost in Transmission: Addressing the Burden of Disease and Pathogenic Mechanisms of Generalized Myasthenia Gravis

69

The Fear of Disappearing, the Fight to Stay Present': Understanding the Needs of Patients With Alzheimer's Disease

70

Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World

71

Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics

72

Treatment Goals in Systemic Lupus Erythematosus: How Are We Raising the Bar?

73

Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing

74

Evolving Therapies in Multiple Sclerosis: BTK Inhibitors